BioSpace News Archive

Drug Development

New Ad-hoc Analysis of Phase 3 HELP Study™ Evaluates Prevention of HAE Attacks with TAKHZYRO® (lanadelumab) During Early Treatment Phase

Data Presented at European Academy of Allergy and Clinical Immunology Congress

June 3, 2019
·
10 min read
Business

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

Astellas Pharma Inc. and Seattle Genetics, Inc. announced that data from the first cohort of a pivotal phase 2 clinical trial known as EV-201 demonstrated that the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44 percent

June 3, 2019
·
11 min read
Biotech Bay

Intrexon Announces Advances in Non-Browning GreenVenus™ Romaine Lettuce

Non-Browning Romaine lettuce demonstrates improved shelf life, reducing food waste and is not subject to regulation as a product produced through genetic engineering by the USDA

June 3, 2019
·
3 min read
Biotech Bay

Invitae introduces new service to make it easier for consumers to receive the medical genetic testing that experts trust

Invitae, a leader in medical genetics, announced the availability of its new service for consumers, which makes it easier for consumers to order and receive the same high-quality, medical genetic testing from Invitae that experts use and trust.

June 3, 2019
·
7 min read
Business

Alpine Immune Sciences Appoints Biopharma Veteran Wayne Gombotz as Chief Technology Officer

Alpine Immune Sciences, Inc. announced the appointment of Wayne Gombotz, PhD as Chief Technology Officer.

June 3, 2019
·
2 min read
Business

FSD Pharma Names Raza Bokhari, M.D. as Permanent CEO

The Board of Directors of FSD Pharma Inc. unanimously voted Raza Bokhari, M.D., Executive Co-Chairman of the Board, as permanent Chief Executive Officer.

June 3, 2019
·
4 min read
Transforming Procurement Process Can Help Medical Devices Manufacturers Achieve Cost Savings | SpendEdge’s Latest Success Story Reveals How

SpendEdge, a leading provider of procurement market intelligence solutions, has announced the completion of their procurement market intelligence engagement for a medical devices company.

June 3, 2019
·
3 min read
Drug Development

Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

Seattle Genetics, Inc. and Astellas Pharma Inc. announced that data from the first cohort of a pivotal phase 2 clinical trial known as EV-201 demonstrated that the investigational agent enfortumab vedotin rapidly shrank tumors in most patients, resulting in an objective response rate of 44 percent.

June 3, 2019
·
11 min read
BioCapital

USP Publishes New and Revised Compounding Standards

Standards help ensure quality compounded preparations to safeguard the well-being of patients

June 3, 2019
·
4 min read
Drug Development

NeuroRX to Present Phase 2 Efficacy Data for NRX-101 at 2019 BIO International Convention

First drug targeting suicidal bipolar depression, awarded FDA Breakthrough Therapy Designation

June 3, 2019
·
3 min read